Agios Pharmaceuticals, Inc. (AGIO)
Market Cap | 2.39B |
Revenue (ttm) | 29.40M |
Net Income (ttm) | -352.62M |
Shares Out | 56.77M |
EPS (ttm) | -6.32 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 450,728 |
Open | 43.37 |
Previous Close | 43.38 |
Day's Range | 41.54 - 43.85 |
52-Week Range | 19.80 - 49.06 |
Beta | 0.77 |
Analysts | Buy |
Price Target | 50.67 (+20.5%) |
Earnings Date | Aug 1, 2024 |
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the ... [Read more]
Financial Performance
In 2023, AGIO's revenue was $26.82 million, an increase of 88.36% compared to the previous year's $14.24 million. Losses were -$352.09 million, 51.9% more than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is $50.67, which is an increase of 20.50% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/f/q/biotech15-2458500.jpg)
Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study
Agios Pharmaceuticals said on Monday its experimental treatment for an inherited blood disorder met the main goal in a late-stage study.
![](https://cdn.snapi.dev/images/v1/p/a/press1-2458486.jpg)
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo –
![](https://cdn.snapi.dev/images/v1/t/a/conf18-2454876.jpg)
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced...
![](https://cdn.snapi.dev/images/v1/v/q/conf7-2429639.jpg)
Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session –
![](https://cdn.snapi.dev/images/v1/9/o/conf2-2408708.jpg)
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced...
![](https://cdn.snapi.dev/images/v1/u/k/press5-2405509.jpg)
Agios Reports Business Highlights and First Quarter 2024 Financial Results
– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 –
![](https://cdn.snapi.dev/images/v1/2/k/conf10-2377712.jpg)
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc...
![](https://cdn.snapi.dev/images/v1/u/w/conf11-2308063.jpg)
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc...
![](https://cdn.snapi.dev/images/v1/x/z/conf4-2288060.jpg)
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha...
![](https://cdn.snapi.dev/images/v1/q/d/press14-2277635.jpg)
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
– Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia – – Presented Positive Results from Phase 2 Portion of the...
![](https://cdn.snapi.dev/images/v1/u/y/conf14-2257346.jpg)
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the...
![](https://cdn.snapi.dev/images/v1/m/u/press19-2219794.jpg)
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
– Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in Non-Transfusion-Dependent Thalassemia –
![](https://cdn.snapi.dev/images/v1/a/h/biotech24-2214290.jpg)
Agios Pharma's stock soars 19.6% on news of positive results in trial of treatment for rare blood disorder
Agios Pharmaceuticals Inc.'s stock AGIO, +2.51% soared 19.6% early Wednesday, after the biotech announced positive results from a Phase 3 trial of a treatment for a rare blood disorder. The trial dubb...
![](https://cdn.snapi.dev/images/v1/q/a/biotech23-2214282.jpg)
Agios' blood disorder drug meets goals of late-stage study
Agios Pharmaceuticals said on Wednesday its drug met the main and secondary goals in a late-stage study in patients with an inherited blood disorder.
![](https://cdn.snapi.dev/images/v1/3/i/press8-2214252.jpg)
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
–Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved for Key Secondary Endpoints of Change From Base...
![](https://cdn.snapi.dev/images/v1/p/3/conf3-2212894.jpg)
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha...
![](https://cdn.snapi.dev/images/v1/k/w/press18-2190242.jpg)
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo – – Improvements Observed in Annualized Rates of Sickle Cell Pain Crises, Marke...
![](https://cdn.snapi.dev/images/v1/o/8/press9-2164916.jpg)
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence; One Study Patient Achieved Hemoglobin Response Endpoint –
![](https://cdn.snapi.dev/images/v1/3/a/conf4-2136189.jpg)
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support Advancem...
![](https://cdn.snapi.dev/images/v1/o/a/press1-2135487.jpg)
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
– First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease –
![](https://cdn.snapi.dev/images/v1/v/g/conf15-2110587.jpg)
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the...
![](https://cdn.snapi.dev/images/v1/l/j/conf16-2040769.jpg)
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha...
![](https://cdn.snapi.dev/images/v1/g/6/press18-2003792.jpg)
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported busi...
![](https://cdn.snapi.dev/images/v1/d/l/press6-2003774.jpg)
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
– Preclinical siRNA Targeting TMPRSS6 is a Potential Disease-Modifying Treatment for Polycythemia Vera – – Agreement Combines Agios' Scientific Expertise and Capabilities in Rare Hematologic Diseases ...
![](https://cdn.snapi.dev/images/v1/q/v/conf8-1969521.jpg)
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
CAMBRIDGE, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the...